Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Dumbrava, E., Sharma, M. R., Carvajal, R. D., Catenacci, D., Emens, L. A., Gadgeel, S. M., Hanna, G. J., Juric, D., Kang, Y., Lee, J., Lee, K., Li, B. T., Moore, K., Pegram, M. D., Pohlmann, P. R., Rasco, D., Spira, A., Tan, A. R., Ackerman, S. E., LeBlanc, H., Dornan, D., Kowanetz, M., Alonso, M. N., Perez, E. A. AMER ASSOC CANCER RESEARCH. 2021

View details for Web of Science ID 000618737700036